Brooke Fruman provides strategic guidance to life science manufacturers on policy developments, reimbursement strategy, and navigating the Inflation Reduction Act (IRA). Her work at Avalere Health has focused on a broad range of topics and therapeutic areas, including drug pricing, payer coverage, and coding strategy for oncology, respiratory, and immunology therapies.
In recent projects, Brooke has helped life science companies strategize and prepare for Medicare drug pricing negotiations under the IRA, specifically focusing on value and evidence positioning, pricing, and strategy development. Brooke also manages complex commercial strategy engagements that consider the market impacts of policy events, such as maximum fair price effectuation, on access strategies.
Prior to joining Avalere Health, Brooke worked as a health policy associate at the Maryland General Assembly. In this position, Brooke conducted extensive research on health policy legislation in Maryland and evaluated the impact of policies that were established in response to the COVID-19 public health emergency, focusing on telehealth services. Additionally, Brooke has also held positions as a researcher at the University of Maryland where she focused on issues such as substance use disorder and early childhood development.